Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: Results from an observational study

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Yale, Jean François ^a   Damci, Taner ^b   Kaiser, Marcel ^c   Karnieli, Eddy ^d   Khunti, Kamlesh ^e   Liebl, Andreas ^f   Baeres, Florian Mm ^g   Svendsen, Anne Louise ^g   Ross, Stuart A ^h  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Practice for Internal Medicine and Diabetology   (Germany)

^d RAMBAM MEDICAL CENTER   (Israel)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f Department for Internal Medicine Center for Diabetes and Metabolism M and i Fachklinik Bad Heilbrunn   (Germany)

^g NOVO NORDISK A S   (Denmark)

^h UNIVERSITY OF CALGARY   (Canada)

Author keywords

Body mass index; Hypoglycaemia; Insulin dose; Insulin therapy; Type 2 diabetes mellitus; Weight

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN DETEMIR; METFORMIN; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84884742947     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-56     Document Type: Article

References (30)

1. Obesity and diabetes in the developing world-a growing challenge. Hossain P, Kawar B, El NM, N Engl J Med 2007 356 213 215 10.1056/NEJMp068177 17229948
2. Metabolic syndrome and type 2 diabetes: can we stop the weight gain with diabetes? Joffe D, Yanagisawa RT, Med Clin North Am 2007 91 1107 1123 ix 10.1016/j.mcna.2007.06.002 17964912
3. Insulin resistance as the core defect in type 2 diabetes mellitus. Goldstein BJ, Am J Cardiol 2002 90 3G 10G 12231073
4. Obesity and the role of adipose tissue in inflammation and metabolism. Greenberg AS, Obin MS, Am J Clin Nutr 2006 83 461S 465S 16470013
5. Weight beneficial treatments for type 2 diabetes. Meneghini LF, Orozco-Beltran D, Khunti K, et al. J Clin Endocrinol Metab 2011 96 3337 3353 10.1210/jc.2011-1074 21900381
6. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Peters AL, Cleve Clin J Med 2009 76 Suppl 5 20 S27 19952300
7. Impact of weight gain on outcomes in type 2 diabetes. Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ, Curr Med Res Opin 2011 27 1431 1438 10.1185/03007995.2011.585396 21599553
8. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Wing RR, Lang W, Wadden TA, et al. Diabetes Care 2011 34 1481 1486 10.2337/dc10-2415 21593294
9. Obesity-related cardiometabolic complications. Cannon CP, Clin Cornerstone 2008 9 11 19 10.1016/S1098-3597(08)60024-1 19046736
10. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Diabetologia 2009 52 65 73 10.1007/s00125-008-1190-x 18985314
11. Barriers to insulin initiation and intensification and how to overcome them. Kunt T, Snoek FJ, Int J Clin Pract Suppl 2009 164 6 10 19751453
12. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Peyrot M, Rubin RR, Khunti K, Prim Care Diabetes 2010 4 Suppl 1 11 S18 20394886
13. Study of Once Daily Levemir (SOLVE): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, Diabetes Obes Metab 2012 14 654 661 10.1111/j.1463-1326.2012.01602.x 22443213
14. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organization, World Health Organ Tech Rep Ser 1995 854 1 452 8594834
15. Obesity: preventing and managing the global epidemic: report on a WHO consultation. World Health Organization, World Health Organ Tech Rep Ser 2000 894 1 253
16. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G, Diabetologia 2008 51 408 416 10.1007/s00125-007-0911-x 18204830
17. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B, Clin Ther 2006 28 1569 1581 10.1016/j.clinthera.2006.10.020 17157113
18. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Blonde L, Merilainen M, Karwe V, Raskin P, Diabetes Obes Metab 2009 11 623 631 10.1111/j.1463-1326.2009.01060.x 19515182
19. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. Holman RR, Thorne KI, Farmer AJ, et al. N Engl J Med 2007 357 1716 1730 10.1056/NEJMoa075392 17890232
20. Managing type 2 diabetes: balancing HbA1c and body weight. Mavian AA, Miller S, Henry RR, Postgrad Med 2010 122 106 117 10.3810/pgm.2010.05.2148 20463420
21. The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. McFarland MS, Knight TN, Brown A, Thomas J, South Med J 2010 103 58 65 10.1097/SMJ.0b013e3181c35776 19996858
22. Are analogue insulins superior to human insulin in clinical practice? Freeman JS, Curr Diab Rep 2010 10 176 183 10.1007/s11892-010-0104-8 20425580
23. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W, Diabetes Obes Metab 2005 7 56 64 10.1111/j.1463-1326.2004.00373.x 15642076
24. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P, Diabetes Care 2006 29 1269 1274 10.2337/dc05-1365 16732007
25. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Raslova K, Tamer SC, Clauson P, Karl D, Clin Drug Investig 2007 27 279 285 10.2165/00044011-200727040-00007 17358100
26. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Dornhorst A, Luddeke HJ, Sreenan S, et al. Int J Clin Pract 2008 62 659 665 10.1111/j.1742-1241.2008.01715.x 18324957
27. Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial. Khunti K, Srinivasan BT, Shutler S, Davies MJ, Diabetes Obes Metab 2010 12 683 688 10.1111/j.1463-1326.2010.01217.x 20590745
28. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Hermansen K, Davies M, Diabetes Obes Metab 2007 9 209 217 10.1111/j.1463-1326.2006.00665.x 17391147
29. Defining the role of insulin detemir in Basal insulin therapy. Morales J, Drugs 2007 67 2557 2584 10.2165/00003495-200767170-00007 18034591
30. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Hallschmid M, Jauch-Chara K, Korn O, et al. Diabetes 2010 59 1101 1107 10.2337/db09-1493 20068139